The Polygenic Score Paradox: Navigating Hope, Hype, and Hurdles in Precision Medicine
This article examines the complex landscape of polygenic risk scores (PRS) in modern medicine, highlighting the tension between their clinical promise and significant scientific limitations. While PRS show utility in specific scenarios, such as improving statin adherence in cardiovascular disease and personalizing breast cancer screening, critics argue these benefits may stem from accompanying clinical attention rather than genetic data alone. A major concern is the reliability crisis; studies indicate that different valid scores can yield contradictory risk assessments for the same individual, with one in five people receiving conflicting high and low-risk classifications. Furthermore, comprehensive analyses suggest PRS perform poorly for general population screening, identifying only a small fraction of future disease cases. The article also underscores profound ethical challenges, particularly the lack of diversity in genetic datasets, which are predominantly derived from individuals of European ancestry. This bias limits the equity and scalability of PRS as a global health tool. Ultimately, the piece urges a measured perspective, cautioning against premature widespread adoption while acknowledging genuine progress in niche diagnostic applications.
Wire timeline
The Polygenic Score Paradox: Navigating Hope, Hype, and Hurdles in Precision Medicine
This article examines the complex landscape of polygenic risk scores (PRS) in modern medicine, highlighting the tension between their clinical promise and significant scientific limitations. While PRS show utility in specific scenarios, such as improving statin adherence in cardiovascular disease and personalizing breast cancer screening, critics argue these benefits may stem from accompanying clinical attention rather than genetic data alone. A major concern is the reliability crisis; studies indicate that different valid scores can yield contradictory risk assessments for the same individual, with one in five people receiving conflicting high and low-risk classifications. Furthermore, comprehensive analyses suggest PRS perform poorly for general population screening, identifying only a small fraction of future disease cases. The article also underscores profound ethical challenges, particularly the lack of diversity in genetic datasets, which are predominantly derived from individuals of European ancestry. This bias limits the equity and scalability of PRS as a global health tool. Ultimately, the piece urges a measured perspective, cautioning against premature widespread adoption while acknowledging genuine progress in niche diagnostic applications.
PHG Foundation